BTIG upgraded Avita Medical (RCEL) to Neutral from Sell with no price target following Q3 results and the CEO change that occurred as a result. Shares are down about 71% year-to-date and the firm thinks the company’s “wounds are starting to heal or at least cannot get materially much worse,” the analyst tells investors. While the firm shares are not quite at a place where it can recommend them, it adds that it is not inclined to recommend selling anymore either.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical’s Earnings Call: Progress Amid Challenges
- Avita Medical’s Financial Struggles and Uncertain Outlook Lead to Sell Rating
- Avita Medical price target lowered to $3 from $4 at Lake Street
- AVITA Medical Reports Q3 2025 Financial Results
- Avita Medical’s Strategic Growth and Recovery: Analyst Recommends Buy Rating